Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other lewy body disorders

Frontiers in Neuroscience

Volumn 10, Issue SEP, 2016, Pages

  Ingelsson, Martin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alpha synuclein oligomers; Biomarker; Lewy body disease; Propagation; Therapeutics; Toxicity

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER;

CELL DEGENERATION; CELL MEMBRANE; CELL SEEDING; CELL TO CELL PROPAGATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CYTOTOXICITY; DIFFUSE LEWY BODY DISEASE; ENDOPLASMIC RETICULUM DYSFUNCTION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MITOCHONDRIAL TOXICITY; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PROCEDURES CONCERNING CELLS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84992103209     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00408     Document Type: Review

References (92)

1. Aasly, J. O., Johansen, K. K., Brønstad, G., Warø, B. J., Majbour, N. K., Varghese, S., et al. (2014). Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6:248. doi: 10.3389/fnagi.2014.00248
2. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813. doi: 10.1002/mds.25421
3. Bae, E. J., Lee, H. J., Rockenstein, E., Ho, D. H., Park, E. B., Yang, N. Y., et al. (2012). Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454-13469. doi: 10.1523/JNEUROSCI.1292-12.2012
4. Bartels, T., Choi, J. G., and Selkoe, D. J. (2011). Alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110. doi: 10.1038/nature10324
5. Bellingham, S. A., Guo, B. B., Coleman, B. M., and Hill, A. F. (2012). Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front. Physiol. 3:124. doi: 10.3389/fphys.2012.00124
6. Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., et al. (2010). EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. U.S.A. 107, 7710-7715. doi: 10.1073/pnas.0910723107
7. Bliederhaeuser, C., Grozdanov, V., Speidel, A., Zondler, L., Ruf, W. P., Bayer, H., et al. (2016). Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol. 131, 379-391. doi: 10.1007/s00401-015-1504-2
8. Braak, H., and Braak, E. (2000). Pathoanatomy of Parkinson's disease. J. Neurol. 247 (Suppl. 2), II3-10. doi: 10.1007/pl00007758
9. Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9
10. Braak, H., de Vos, R. A., Bohl, J., and Del Tredici, K. (2006). Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67-72. doi: 10.1016/j.neulet.2005.11.012
11. Brännström, K., Lindhagen-Persson, M., Gharibyan, A. L., Iakovleva, I., Vestling, M., Sellin, M. E., et al. (2014). A generic method for design of oligomer-specific antibodies. PLoS ONE 9:e90857. doi: 10.1371/journal.pone.0090857
12. Burré, J. (2015). The synaptic function of alpha-synuclein. J. Parkinsons. Dis. 5, 699-713. doi: 10.3233/JPD-150642
13. Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., and Südhof, T. C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667. doi: 10.1126/science.1195227
14. Burré, J., Vivona, S., Diao, J., Sharma, M., Brunger, A. T., and Südhof, T. C. (2013). Properties of native brain alpha-synuclein. Nature 498, E4-E6. discussion: E6-E7. doi: 10.1038/nature12125
15. Cappai, R., Leck, S. L., Tew, D. J., Williamson, N. A., Smith, D. P., Galatis, D., et al. (2005). Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 1377-1379. doi: 10.1096/fj.04-3437fje
16. Chandra, S., Chen, X., Rizo, J., Jahn, R., and Südhof, T. C. (2003). A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. 278, 15313-15318. doi: 10.1074/jbc.M213128200
17. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169. doi: 10.1016/S0140-6736(04)17103-1
18. Chen, R. H., Wislet-Gendebien, S., Samuel, F., Visanji, N. P., Zhang, G., Marsilio, D., et al. (2013). Alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J. Biol. Chem. 288, 7438-7449. doi: 10.1074/jbc.M112.439497
19. Chinta, S. J., Mallajosyula, J. K., Rane, A., and Andersen, J. K. (2010). Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486, 235-239. doi: 10.1016/j.neulet.2010.09.061
20. Choi, B. K., Choi, M. G., Kim, J. Y., Yang, Y., Lai, Y., Kweon, D. H., et al. (2013). Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U.S.A. 110, 4087-4092. doi: 10.1073/pnas.1218424110
21. Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., et al. (2012a). Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32, 3306-3320. doi: 10.1523/JNEUROSCI.5367-11.2012
22. Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., and Lee, M. K. (2012b). Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32, 3301-3305. doi: 10.1523/JNEUROSCI.5368-11.2012
23. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320. doi: 10.1038/3311
24. Conway, K. A., Lee, S.-J., Rochet, J.-C., Ding, T. T., Williamson, R. E., and Lansbury, P. T. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations limked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 571-576. doi: 10.1073/pnas.97.2.571
25. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., et al. (2007). Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220-9232. doi: 10.1523/JNEUROSCI.2617-07.2007
26. Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., et al. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7:42. doi: 10.1186/1750-1326-7-42
27. Danzer, K. M., Krebs, S. K., Wolff, M., Birk, G., and Hengerer, B. (2009). Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 111, 192-203. doi: 10.1111/j.1471-4159.2009.06324.x
28. Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., and Selkoe, D. (2013). In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371-6385. doi: 10.1074/jbc.M112.403311
29. Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., et al. (2016). Alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci. Transl. Med. 8:342ra378. doi: 10.1126/scitranslmed.aaf3634
30. Diógenes, M. J., Dias, R. B., Rombo, D. M., Vicente Miranda, H., Maiolino, F., Guerreiro, P., et al. (2012). Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750-11762. doi: 10.1523/JNEUROSCI.0234-12.2012
31. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., et al. (2008). EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566. doi: 10.1038/nsmb.1437
32. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., et al. (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851. doi: 10.1523/JNEUROSCI.5699-09.2010
33. Esterbauer, H., Schaur, R. J., and Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81-128. doi: 10.1016/0891-5849(91)90192-6
34. Fagerqvist, T., Lindström, V., Nordström, E., Lord, A., Tucker, S. M., Su, X., et al. (2013a). Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 126, 131-144. doi: 10.1111/jnc.12175
35. Fagerqvist, T., Näsström, T., Ihse, E., Lindström, V., Sahlin, C., Tucker, S. M., et al. (2013b). Off-pathway alpha-synuclein oligomers seem to alter alpha-synuclein turnover in a cell model but lack seeding capability in vivo. Amyloid 20, 233-244. doi: 10.3109/13506129.2013.835726
36. Fauvet, B., Mbefo, M. K., Fares, M. B., Desobry, C., Michael, S., Ardah, M. T., et al. (2012). Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J. Biol. Chem. 287, 15345-15364. doi: 10.1074/jbc.M111.318949
37. Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., et al. (2014). Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34, 9441-9454. doi: 10.1523/JNEUROSCI.5314-13.2014
38. Hansen, C., Angot, E., Bergström, A. L., Steiner, J. A., Pieri, L., Paul, G., et al. (2011). Alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725. doi: 10.1172/JCI43366
39. Hansson, O., Hall, S., Ohrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., et al. (2014). Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res. Ther. 6:25. doi: 10.1186/alzrt255
40. Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., et al. (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805-820. doi: 10.1007/s00401-014-1343-6
41. Hong, D. P., Fink, A. L., and Uversky, V. N. (2008). Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383, 214-223. doi: 10.1016/j.jmb.2008.08.039
42. Hong, D. P., Fink, A. L., and Uversky, V. N. (2009). Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta 1794, 282-290. doi: 10.1016/j.bbapap.2008.09.026
43. Houlden, H., and Singleton, A. B. (2012). The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124, 325-338. doi: 10.1007/s00401-012-1013-5
44. Jakes, R., Spillantini, M. G., and Goedert, M. (1994). Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32. doi: 10.1016/0014-5793(94)00395-5
45. Karpinar, D. P., Balija, M. B., Kügler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256-3268. doi: 10.1038/emboj.2009.257
46. Kaufmann, T. J., Harrison, P. M., Richardson, M. J., Pinheiro, T. J., and Wall, M. J. (2016). Intracellular soluble alpha-synuclein oligomers reduce pyramidal cell excitability. J. Physiol. 594, 2751-2772. doi: 10.1113/JP271968
47. Kim, J. (1997). Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol. Cells 7, 78-83.
48. Klucken, J., Poehler, A. M., Ebrahimi-Fakhari, D., Schneider, J., Nuber, S., Rockenstein, E., et al. (2012). Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8, 754-766. doi: 10.4161/auto.19371
49. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., and Olanow, C. W. (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506. doi: 10.1038/nm1747
50. Kramer, M. L., and Schulz-Schaeffer, W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405-1410. doi: 10.1523/JNEUROSCI.4564-06.2007
51. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108. doi: 10.1038/ng0298-106
52. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., et al. (2002). Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102. doi: 10.1016/S0022-2836(02)00735-0
53. Lee, H. J., Suk, J. E., Patrick, C., Bae, E. J., Cho, J. H., Rho, S., et al. (2010). Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262-9272. doi: 10.1074/jbc.M109.081125
54. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., et al. (2013). G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471. doi: 10.1002/ana.23894
55. Li, J. Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503. doi: 10.1038/nm1746
56. Lindström, V., Fagerqvist, T., Nordström, E., Eriksson, F., Lord, A., Tucker, S., et al. (2014). Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol. Dis. 69, 134-143. doi: 10.1016/j.nbd.2014.05.009
57. Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., et al. (2014). Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 127, 861-879. doi: 10.1007/s00401-014-1256-4
58. Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., et al. (2005). Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868. doi: 10.1016/j.neuron.2005.05.010
59. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., et al. (2011). Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6:e19338. doi: 10.1371/journal.pone.0019338
60. Mendez, I., Viñuela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H., et al. (2008). Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507-509. doi: 10.1038/nm1752
61. Nässträm, T., Fagerqvist, T., Barbu, M., Karlsson, M., Nikolajeff, F., Kasrayan, A., et al. (2011). The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic. Biol. Med. 50, 428-437. doi: 10.1016/j.freeradbiomed.2010.11.027
62. Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., Ingelsson, M., et al. (2009). The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. Biochem. Biophys. Res. Commun. 378, 872-876. doi: 10.1016/j.bbrc.2008.12.005
63. Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., et al. (2008). Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3:e1867. doi: 10.1371/annotation/9282f173-df82-4b70-9120-b4e62b3dacb1
64. Paleologou, K. E., Kragh, C. L., Mann, D. M., Salem, S. A., Al-Shami, R., Allsop, D., et al. (2009). Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093-1101. doi: 10.1093/brain/awn349
65. Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., and Ghafourifar, P. (2009). Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int. J. Biochem. Cell Biol. 41, 2015-2024. doi: 10.1016/j.biocel.2009.05.008
66. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H., and Kim, J. W. (2011). Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7, 215-222. doi: 10.3988/jcn.2011.7.4.215
67. Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., et al. (2014). Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov. Disord. 29, 1019-1027. doi: 10.1002/mds.25772
68. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. doi: 10.1126/science.276.5321.2045
69. Proukakis, C., Dudzik, C. G., Brier, T., Mackay, D. S., Cooper, J. M., Millhauser, G. L., et al. (2013). A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064. doi: 10.1212/WNL.0b013e31828727ba
70. Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., and Fink, A. L. (2007). Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282, 5862-5870. doi: 10.1074/jbc.M608126200
71. Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., et al. (2014). Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137, 1496-1513. doi: 10.1093/brain/awu057
72. Sanchez-Guajardo, V., Annibali, A., Jensen, P. H., and Romero-Ramos, M. (2013). Alpha-synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J. Neuropathol. Exp. Neurol. 72, 624-645. doi: 10.1097/NEN.0b013e31829768d2
73. Shamoto-Nagai, M., Maruyama, W., Hashizume, Y., Yoshida, M., Osawa, T., Riederer, P., et al. (2007). In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural. Transm. (Vienna) 114, 1559-1567. doi: 10.1007/s00702-007-0789-2
74. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003). The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595. doi: 10.1016/S0896-6273(03)00024-2
75. Sierks, M. R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P., and Prasad, S. (2011). CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol. (Camb). 3, 1188-1196. doi: 10.1039/c1ib00018g
76. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). a-Synuclein locus triplication causes Parkinson's disease. Science 302, 841. doi: 10.1126/science.1090278
77. Spencer, B., Williams, S., Rockenstein, E., Valera, E., Xin, W., Mante, M., et al. (2016). a-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann. Clin. Translat. Neurol. doi: 10.1002/acn3.321. [Epub ahead of print].
78. Theillet, F. X., Binolfi, A., Bekei, B., Martorana, A., Rose, H. M., Stuiver, M., et al. (2016). Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature 530, 45-50. doi: 10.1038/nature16531
79. Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166. doi: 10.1016/j.bbrc.2006.08.024
80. Tosatto, L., Horrocks, M. H., Dear, A. J., Knowles, T. P., Dalla Serra, M., Cremades, N., et al. (2015). Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants. Sci. Rep. 5:16696. doi: 10.1038/srep16696
81. Unterberger, U., Lachmann, I., Voigtländer, T., Pirker, W., Berghoff, A. S., Flach, K., et al. (2014). Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study. Clin. Neuropathol. 33, 329-334. doi: 10.5414/NP300796
82. Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., and Fink, A. L. (2002). Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517, 239-244. doi: 10.1016/S0014-5793(02)02638-8
83. Volles, M. J., and Lansbury, P. T. Jr. (2002). Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602. doi: 10.1021/bi0121353
84. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., et al. (2001). Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819. doi: 10.1021/bi0102398
85. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T. Jr. (1996). NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715. doi: 10.1021/bi961799n
86. Wilms, H., Rosenstiel, P., Romero-Ramos, M., Arlt, A., Schäfer, H., Seegert, D., et al. (2009). Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int. J. Immunopathol. Pharmacol. 22, 897-909. doi: 10.1177/039463200902200405
87. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 108, 4194-4199. doi: 10.1073/pnas.1100976108
88. Zaltieri, M., Grigoletto, J., Longhena, F., Navarria, L., Favero, G., Castrezzati, S., et al. (2015). Alpha-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J. Cell Sci. 128, 2231-2243. doi: 10.1242/jcs.157867
89. Zarranz, J. J., Alegre, J., Gémez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173. doi: 10.1002/ana.10795
90. Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., et al. (2005). Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542. doi: 10.1096/fj.04-2751com
91. Zhou, W., Gallagher, A., Hong, D. P., Long, C., Fink, A. L., and Uversky, V. N. (2009). At low concentrations, 3, 4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation. J. Mol. Biol. 388, 597-610. doi: 10.1016/j.jmb.2009.03.053
92. Zhou, W., Long, C., Reaney, S. H., Di Monte, D. A., Fink, A. L., and Uversky, V. N. (2010). Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim. Biophys. Acta 1802, 322-330. doi: 10.1016/j.bbadis.2009.12.004